Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors

被引:13
作者
Balan, Daniel [1 ,2 ,3 ]
Martha, Orsolya [2 ]
Chibelean, Calin Bogdan [2 ]
Tataru, Sabin [2 ]
Voidezan, Septimiu [4 ]
Sin, Anca [1 ]
Matei, Victor Deliu [5 ]
Vartolomei, Mihai Dorin [1 ,2 ,5 ,6 ]
Lucarelli, Giuseppe [7 ]
Cioffi, Antonio [5 ]
Del Giudice, Francesco [8 ]
De Berardinis, Ettore [8 ]
Borda, Angela [9 ]
Busetto, Gian Maria [8 ]
Ferro, Matteo [5 ]
Pytel, Akos [3 ]
Porav-Hodade, Daniel [2 ]
机构
[1] Univ Med & Pharm, Dept Cell & Mol Biol, Targu Mures, Romania
[2] Univ Med & Pharm, Dept Urol, Targu Mures, Romania
[3] Univ Pecs, Dept Urol, Pecs, Hungary
[4] Univ Med & Pharm, Dept Epidemiol, Targu Mures, Romania
[5] European Inst Oncol, Div Urol, Via Ripamonti 435, I-20141 Milan, Italy
[6] Med Univ Vienna, Dept Urol, Vienna, Austria
[7] Univ Bari, Dept Emergency & Organ Transplantat, Urol Androl & Kidney Transplantat Unit, Bari, Italy
[8] Sapienza Univ Rome, Dept Urol, Rome, Italy
[9] Univ Med & Pharm, Dept Histol, Targu Mures, Romania
关键词
G1 and G2 grade nonmuscle invasive bladder cancer; long-term; overall survival; progression; recurrence; BACILLUS-CALMETTE-GUERIN; FOLLOW-UP; UROTHELIAL CARCINOMA; ONCOLOGICAL OUTCOMES; CANCER; PROGRESSION; THERAPY; T1; RECURRENCE; GUIDELINES;
D O I
10.1097/MD.0000000000010522
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs). Secondary aim was to investigate clinical and pathologic prognostic factors for OS of Ta patients, except G3/high grade (HG). A total of 243 patients, retrospectively selected, with Ta nonmuscle invasive bladder cancer (NMIBC) underwent TURBT between January 2006 and December 2008 (median follow-up 109 months). Inclusion criteria were: Ta at first manifestation, G1 or G2 grade with no associated carcinoma in situ (CIS). Seventy-nine patients were excluded due to concomitant CIS (1), G3/HG tumors (47), and lost to follow-up (31). Ethical approval was obtained from the Ethical Committee of the Mures County Hospital. Statistical analysis was performed using STATA 11.0. Following inclusion criteria, 164 patients with primary G1 or G2 Ta tumors, were enrolled. Recurrence was observed in 26 (15.8%) and progression in 5 (3%) patients. Ten-year survival in G1 patients was 67.8% (CI 54.3-78.1) and in G2 patients 59% (CI 49-67.3) (P=.31). Univariable and multivariable logistic regression analysis underlined that advanced age at diagnosis (hazard ratio [HR] 1.10) and no Bacillus Calmette-Guerin (BCG) treatment (HR 0.24 and 0.29) were independent predictors for death at 10 years after diagnosis. Long-term analysis confirms that patients with well differentiated (G1) and moderately well differentiated (G2) Ta tumors have similar OS. A longer OS was even reported in those who underwent BCG adjuvant therapy.
引用
收藏
页数:6
相关论文
共 31 条
  • [1] Bladder cancer biomarkers: current developments and future implementation
    Alvarez, Alonso
    Lokeshwar, Vinata B.
    [J]. CURRENT OPINION IN UROLOGY, 2007, 17 (05) : 341 - 346
  • [2] [Anonymous], 2017, EUR UROL
  • [3] [Anonymous], EUR ASS UROL
  • [4] [Anonymous], 2016, UROL ONCOL
  • [5] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
    Babjuk, Marko
    Boehle, Andreas
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Hernandez, Virginia
    Kaasinen, Eero
    Palou, Joan
    Roupret, Morgan
    van Rhijn, Bas W. G.
    Shariat, Shahrokh F.
    Soukup, Viktor
    Sylvester, Richard J.
    Zigeuner, Richard
    [J]. EUROPEAN UROLOGY, 2017, 71 (03) : 447 - 461
  • [6] Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer
    Cheng, CW
    Chan, SFP
    Chan, LW
    Chan, CK
    Ng, CF
    Cheung, HY
    Chan, SYE
    Wong, WS
    Lai, FMM
    To, KF
    Li, ML
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2005, 12 (05) : 449 - 455
  • [7] Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer
    Cotte, Juliette
    Roupret, Morgan
    [J]. EUROPEAN UROLOGY, 2017, 72 (01) : 152 - 152
  • [8] Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature
    Crivelli, Joseph J.
    Xylinas, Evanguelos
    Kluth, Luis A.
    Rieken, Malte
    Rink, Michael
    Shariat, Shahrokh F.
    [J]. EUROPEAN UROLOGY, 2014, 65 (04) : 742 - 754
  • [9] Superficial bladder carcinoma treated with bacillus Calmette-Guerin: Progression-free and disease specific survival with minimum 10-year follow-up
    Davis, JW
    Sheth, SI
    Doviak, MJ
    Schellhammer, PF
    [J]. JOURNAL OF UROLOGY, 2002, 167 (02) : 494 - 500
  • [10] T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
    De Berardinis, E.
    Busetto, G. M.
    Antonini, G.
    Giovannone, R.
    Gentile, V.
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2011, 43 (04) : 1047 - 1057